Is ATRA or AURA more undervalued in 2026?

CirclFi compares Atara Biotherapeutics, Inc. (ATRA) and Aura Biosciences, Inc. (AURA) using 13 institutional-grade valuation models. ATRA has a Quality of Company score of 4.8/10 while AURA scores 5.2/10.

Which is a better buy — ATRA or AURA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ATRA and AURA valuations compare?

ATRA at $11.26 and AURA at $7.50 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ATRA vs AURA Valuation Comparison 2026 — Intrinsic Value Analysis

ATRA

Biotechnology

Atara Biotherapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$11.26

Last close

Models

11/13

Active

AURA

Biotechnology

Aura Biosciences, Inc.

Quality

5.2

out of 10

Value Trap

SAFE

Price

$7.50

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ATRA Fair Value	ATRA Upside	AURA Fair Value	AURA Upside
Bayesian DCF	Intrinsic	$2.31	-79.5%	$2.39	-68.1%
Earnings Power Value	Intrinsic	$49.72	+496.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	—	—	$0.59	-92.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATRA vs AURA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATRA vs AURA — Which Stock Is More Undervalued?

AURA scores higher with a 5.2/10 quality rating vs ATRA's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atara Biotherapeutics, Inc. (ATRA) and Aura Biosciences, Inc. (AURA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATRA currently trades at $11.26 with a QOC of 4.8/10, while AURA trades at $7.50 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).